T T Seppälä1,2, A Latchford3,4, I Negoi5, A Sampaio Soares6, R Jimenez-Rodriguez7, L Sánchez-Guillén8, D G Evans9, N Ryan10,11, E J Crosbie10, M Dominguez-Valentin12, J Burn13, M Kloor14,15, M von Knebel Doeberitz14,15, F J B van Duijnhoven16, P Quirke17, J R Sampson18, P Møller12,19, G Möslein20,19. 1. Department of Surgery, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland. 2. Department of Surgical Oncology, Johns Hopkins Hospital, Baltimore Maryland, USA. 3. Department of Cancer and Surgery, Imperial College London, UK. 4. St Mark's Hospital, London North West Healthcare NHS Trust, London, UK. 5. Department of Surgery, Emergency Hospital of Bucharest, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 6. Hospital Prof. Dr Fernando Fonseca, EPE, Lisbon, Portugal. 7. Department of Surgery, Hospital Universitario Virgen del Rocío, Seville, Spain. 8. Colorectal Unit, Department of General Surgery, Elche University General Hospital Elche, Alicante, Spain. 9. Manchester Centre for Genomic Medicine, Division of Evolution and Genomic Sciences, University of Manchester, Manchester University Hospitals NHS Foundation Trust, UK. 10. Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK. 11. Centre for Academic Women's Health, University of Bristol, Bristol, UK. 12. Department of Tumour Biology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. 13. Faculty of Medical Sciences, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. 14. Department of Applied Tumour Biology, Institute of Pathology, University Hospital Heidelberg, Germany. 15. Cooperation Unit Applied Tumour Biology, German Cancer Research Centre, Heidelberg, Germany. 16. Division of Human Nutrition and Health, Wageningen University and Research, Wageningen, the Netherlands. 17. Pathology and Data Analytics, School of Medicine, University of Leeds, Leeds, UK. 18. Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff University School of Medicine, Heath Park, Cardiff, UK. 19. University of Witten/Herdecke, Witten, Germany. 20. Centre for Hereditary Tumours, Bethesda Hospital, Duisburg, Germany.
Abstract
BACKGROUND: Lynch syndrome is the most common genetic predisposition for hereditary cancer but remains underdiagnosed. Large prospective observational studies have recently increased understanding of the effectiveness of colonoscopic surveillance and the heterogeneity of cancer risk between genotypes. The need for gene- and gender-specific guidelines has been acknowledged. METHODS: The European Hereditary Tumour Group (EHTG) and European Society of Coloproctology (ESCP) developed a multidisciplinary working group consisting of surgeons, clinical and molecular geneticists, pathologists, epidemiologists, gastroenterologists, and patient representation to conduct a graded evidence review. The previous Mallorca guideline format was used to revise the clinical guidance. Consensus for the guidance statements was acquired by three Delphi voting rounds. RESULTS: Recommendations for clinical and molecular identification of Lynch syndrome, surgical and endoscopic management of Lynch syndrome-associated colorectal cancer, and preventive measures for cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer spectrum. Manchester consensus guidelines for gynaecological management were endorsed. Executive and layperson summaries were provided. CONCLUSION: The recommendations from the EHTG and ESCP for identification of patients with Lynch syndrome, colorectal surveillance, surgical management of colorectal cancer, lifestyle and chemoprevention in Lynch syndrome that reached a consensus (at least 80 per cent) are presented.
BACKGROUND:Lynch syndrome is the most common genetic predisposition for hereditary cancer but remains underdiagnosed. Large prospective observational studies have recently increased understanding of the effectiveness of colonoscopic surveillance and the heterogeneity of cancer risk between genotypes. The need for gene- and gender-specific guidelines has been acknowledged. METHODS: The European Hereditary Tumour Group (EHTG) and European Society of Coloproctology (ESCP) developed a multidisciplinary working group consisting of surgeons, clinical and molecular geneticists, pathologists, epidemiologists, gastroenterologists, and patient representation to conduct a graded evidence review. The previous Mallorca guideline format was used to revise the clinical guidance. Consensus for the guidance statements was acquired by three Delphi voting rounds. RESULTS: Recommendations for clinical and molecular identification of Lynch syndrome, surgical and endoscopic management of Lynch syndrome-associated colorectal cancer, and preventive measures for cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer spectrum. Manchester consensus guidelines for gynaecological management were endorsed. Executive and layperson summaries were provided. CONCLUSION: The recommendations from the EHTG and ESCP for identification of patients with Lynch syndrome, colorectal surveillance, surgical management of colorectal cancer, lifestyle and chemoprevention in Lynch syndrome that reached a consensus (at least 80 per cent) are presented.
Authors: Alejandro Hernandez-Sanchez; Mark Grossman; Kevin Yeung; Shizuko S Sei; Steven Lipkin; Matthias Kloor Journal: J Immunother Cancer Date: 2022-06 Impact factor: 12.469
Authors: Richard Gallon; Peter Gawthorpe; Rachel L Phelps; Christine Hayes; Gillian M Borthwick; Mauro Santibanez-Koref; Michael S Jackson; John Burn Journal: Cancers (Basel) Date: 2021-01-22 Impact factor: 6.639